Discipline of Surgery, The Lambe Institute for Translational Research, National University of Ireland, Galway, Galway, H91YR71, Ireland.
Department of Surgery, Galway University Hospitals, Galway, H91YR71, Republic of Ireland.
Langenbecks Arch Surg. 2023 May 5;408(1):180. doi: 10.1007/s00423-023-02911-7.
No randomised clinical trials (RCTs) have simultaneously compared the safety of open (OA), transperitoneal laparoscopic (TLA), posterior retroperitoneal (PRA), and robotic adrenalectomy (RA) for resecting adrenal tumours.
To evaluate outcomes for OA, TLA, PRA, and RA from RCTs.
A NMA was performed according to PRISMA-NMA guidelines. Analysis was performed using R packages and Shiny.
Eight RCTs with 488 patients were included (mean age: 48.9 years). Overall, 44.5% of patients underwent TLA (217/488), 37.3% underwent PRA (182/488), 16.4% underwent RA (80/488), and just 1.8% patients underwent OA (9/488). The mean tumour size was 35 mm in largest diameter with mean sizes of 44.3 mm for RA, 40.9 mm for OA, 35.5 mm for TLA, and 34.4 mm for PRA (P < 0.001). TLA had the lowest blood loss (mean: 50.6 ml), complication rates (12.4%, 14/113), and conversion to open rates (1.3%, 2/157), while PRA had the shortest intra-operative duration (mean: 94 min), length of hospital stay (mean: 3.7 days), lowest visual analogue scale pain scores post-operatively (mean: 3.7), and was most cost-effective (mean: 1728 euros per case). At NMA, there was a significant increase in blood loss for OA (mean difference (MD): 117.00 ml (95% confidence interval (CI): 1.41-230.00)) with similar blood loss observed for PRA (MD: - 10.50 (95% CI: - 83.40-65.90)) compared to TLA.
LTA and PRA are important contemporary options in achieving favourable outcomes following adrenalectomy. The next generation of RCTs may be more insightful for comparison surgical outcomes following RA, as this approach is likely to play a future role in minimally invasive adrenalectomy.
CRD42022301005.
目前尚无随机临床试验(RCT)同时比较开放(OA)、经腹腔腹腔镜(TLA)、后腹膜后(PRA)和机器人肾上腺切除术(RA)切除肾上腺肿瘤的安全性。
评估 RCT 中 OA、TLA、PRA 和 RA 的结果。
根据 PRISMA-NMA 指南进行 NMA。分析使用 R 包和 Shiny 进行。
纳入 8 项 RCT 共 488 例患者(平均年龄:48.9 岁)。总体而言,44.5%的患者接受 TLA(217/488),37.3%的患者接受 PRA(182/488),16.4%的患者接受 RA(80/488),只有 1.8%的患者接受 OA(9/488)。最大直径的平均肿瘤大小为 35mm,RA 为 44.3mm,OA 为 40.9mm,TLA 为 35.5mm,PRA 为 34.4mm(P<0.001)。TLA 出血量最低(平均:50.6ml),并发症发生率最低(12.4%,14/113),中转开腹率最低(1.3%,2/157),而 PRA 术中时间最短(平均:94min),住院时间最短(平均:3.7 天),术后视觉模拟评分疼痛最低(平均:3.7),且最具成本效益(平均:每例 1728 欧元)。在 NMA 中,OA 的出血量显著增加(平均差值(MD):117.00ml(95%置信区间(CI):1.41-230.00)),与 TLA 相比,PRA 的出血量相似(MD:-10.50(95%CI:-83.40-65.90))。
LTA 和 PRA 是肾上腺切除术后获得良好结果的重要当代选择。下一代 RCT 可能会更深入地比较 RA 后手术结果,因为这种方法很可能在微创肾上腺切除术中发挥未来作用。
PROSPERO 注册:CRD42022301005。